我要投票 Jinhe金河在饲料添加剂行业中的票数:130
· 外 推 电 报 ·
2025-03-13 01:35:15 星期四

【Jinhe金河是哪个国家的品牌?】

Jinhe金河是什么牌子?「Jinhe金河」是 金河生物科技股份有限公司 旗下著名品牌。该品牌发源于内蒙古,由创始人王东晓在1990期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Jinhe金河品牌出海!通过在本页面挂载Jinhe金河品牌的产品链接和联系邮箱,可以提高Jinhe金河产品曝光!跨境电商爆单神器,目前只要100元/年哦~

金河生物科技股份有限公司是一家生产和销售饲用金霉素及动物保健品为主的民营控股企业,1998年被国家科委认定为“国家重点高新技术企业”,同时也是内蒙古自治区60家重点企业之一。

公司位于青山南麓、黄河之滨的内蒙古托克托县境内,与亚洲最大的火力发电厂——大唐托克托电厂比邻相依,并与中国最大的露天煤矿——准格尔煤田隔(黄)河相望,具有得天独厚的地理优势和资源优势。

公司现拥有国际上先进的发酵生产设备和产品质量检测设备,主要工艺流程全部采用微机自动控制,现有发酵吨位5794立方米,金霉素的发酵规模居世界前列。

其主导产品“牧星”、“金河”牌饲用金霉素目前年生产能力5.3万多吨,连续六次顺利通过美国联邦政府食品与药品管理总署(FDA)的质量验收。

产品主要出口到美国、加拿大、东南亚等国家和地区,同时行销网络遍布国内各省、市(自治区),市场前景十分广阔。

作为一家高新技术企业,金河生物科技股份有限公司近年来得到了迅猛的发展,这主要得益于企业以人为本的发展思路和强大的技术支撑。

通过人才的引进和人力资源的合理配置,使企业逐步形成了自己的人才梯队,在充分发挥人才优势的群体效应的同时,在生产技术领域不断地完善与创新,为企业在知识经济时代异军突起奠定了坚实的基础。

良好的信誉、卓越的品质源于企业严格的管理和对技术创新孜孜不倦的追求。

2001-2002年,企业先后顺利通过了ISO9002质量体系认证和国家兽药企业GMP验收。

从1994年起,企业连续六次顺利通过美国联邦政府食品药品管理总署(FDA)的质量验收,并被国家九部委认定为农业产业化国家重点龙头企业。

金河生物科技股份有限公司在未来的发展进程中,将按照“面向市场、优化结构、整合资源、提高效益”的发展构想,以发酵工业为载体,以调整产品结构为主线,走外延与内涵相结合扩大再生产的科技强企之路,通过与行业精英联盟,实现资产优化和管理升级,结合基因工程等高科技手段的探索与研究,全面提升企业的整体素质和核心竞争力,进一步增强企业的经济实力和发展后劲,为民族工业的繁荣和发展做出新的更大的贡献。

英文翻译:Jinhe Biotechnology Co., Ltd. is a private holding enterprise mainly engaged in the production and sale of feed chlortetracycline and animal health products. In 1998, it was recognized as a "national key high-tech enterprise" by the State Science and Technology Commission, and also one of the 60 key enterprises in Inner Mongolia Autonomous Region. The company is located in Tuoketuo County, Inner Mongolia, on the south foot of Qingshan mountain and the Bank of the Yellow River. It is adjacent to Datang Tuoketuo Power Plant, the largest thermal power plant in Asia, and across the (yellow) River from Jungar coal field, the largest open-pit coal mine in China. It has unique geographical advantages and resource advantages. The company now has advanced fermentation production equipment and product quality testing equipment in the world. The main technological process is all controlled by computer automatically. The current fermentation tonnage is 5794 cubic meters, and the fermentation scale of chlortetracycline ranks the top in the world. Its leading products "muxing" and "Jinhe" brand feed aureomycin currently have an annual production capacity of more than 53000 tons, and have successfully passed the quality acceptance of the United States Federal Food and Drug Administration (FDA) for six consecutive times. The products are mainly exported to the United States, Canada, Southeast Asia and other countries and regions. At the same time, the marketing network is all over the domestic provinces, cities (autonomous regions), and the market prospect is very broad. As a high-tech enterprise, Jinhe Biotechnology Co., Ltd. has developed rapidly in recent years, which is mainly due to the people-oriented development ideas and strong technical support of the enterprise. Through the introduction of talents and the rational allocation of human resources, the enterprise has gradually formed its own talent echelon. While giving full play to the group effect of talent advantages, it has constantly improved and innovated in the field of production technology, laying a solid foundation for the emergence of enterprises in the era of knowledge economy. Good reputation and excellent quality come from the strict management of the enterprise and the tireless pursuit of technological innovation. From 2001 to 2002, the company has successfully passed ISO9002 quality system certification and GMP acceptance of national veterinary drug enterprises. Since 1994, the company has successfully passed the quality acceptance of the United States Federal Food and Drug Administration (FDA) for six consecutive times, and has been recognized as the national key leading enterprise of agricultural industrialization by nine ministries and commissions. In the future development process, Jinhe Biotechnology Co., Ltd. will follow the development concept of "facing the market, optimizing the structure, integrating the resources and improving the efficiency", take the fermentation industry as the carrier, adjust the product structure as the main line, take the road of expanding the renewable production through the combination of extension and connotation, and realize the asset optimization and management upgrading through the alliance with the industry elite, Combined with the exploration and research of high-tech means such as genetic engineering, we will comprehensively improve the overall quality and core competitiveness of enterprises, further enhance the economic strength and development potential of enterprises, and make new and greater contributions to the prosperity and development of national industry.

本文链接: https://www.waitui.com/brand/cc6e5eebb.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

平安好医生:2024年营收48.1亿元,首次全年盈利

36氪获悉,平安好医生发布2024年年度业绩公告。报告期内,公司录得营收48.1亿元,调整后净利润1.58亿元。其中,综合金融客户端(F端)及企业端(B端)业务收入同比增长17.2%。F端业务收入超24亿元,同比增长9.6%。B端业务收入同比提升32.7%,录得收入超14亿。截至报告期末,累计服务的企业客户数达2049家,较去年同期增长35.9%。

2小时前

热门中概股美股盘前多数下跌,小鹏汽车跌超6%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,小鹏汽车跌超6%,极氪跌超4%,哔哩哔哩跌超3%,百度、微博、蔚来、理想汽车跌超1%;小马智行涨超2%,知乎涨超1%。

2小时前

蓝思科技:拟发行H股股票并在香港联交所上市

36氪获悉,蓝思科技发布公告,公司拟发行境外上市外资股(H股)股票,并申请在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。公司将充分考虑现有股东利益及境内外资本市场情况,在股东大会决议有效期内(即经公司股东大会审议通过之日起24个月或同意延长的其他期限)择机完成本次发行上市。

2小时前

鸿博股份:子公司英博数科与百川智能解除云服务协议

36氪获悉,鸿博股份发布公告,2023年12月4日,公司全资子公司英博数科与百川智能签署了《云服务协议》,英博数科向百川智能提供一定规模的智算服务器所有的算力和资源以及配套软件、应用,以及技术服务,合同期限为三年,自2024年1月30日至2027年1月31日,合同约定开始履行日期为2024年1月30日。自合同签订起,英博数科与百川智能始终致力于推进原合同的实施,并与百川智能建立了良好的合作关系,但受不可抗力因素影响,原合同已无法继续履行,公司与百川智能于近日签署《确认函》,经双方协商一致,停止原合同相关合作,且双方不存在争议,互不承担责任。由于原合同尚未产生收入,合同解除预计不会对公司财务及经营状况造成重大不利影响。

2小时前

交易员提高对美联储降息的押注,预计年内至少降息两次

交易员提高对美联储降息的押注,预计年内至少降息两次。(财联社)

2小时前

本页详细列出关于鸣牌的品牌信息,含品牌所属公司介绍,鸣牌所处行业的品牌地位及优势。
咨询